Suscripción a Biblioteca: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Publicado 4 números por año

ISSN Imprimir: 0731-8898

ISSN En Línea: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Breast Cancer and Ovarian Cancer Genetics: An Update

Volumen 27, Edición 4, 2008, pp. 245-256
DOI: 10.1615/JEnvironPatholToxicolOncol.v27.i4.10
Get accessGet access

SINOPSIS

The purpose of this report on breast cancer and ovarian cancer genetics is to review the evidence for the efficacy of surveillance for early detection, bilateral prophylactic mastectomy, prophylactic oophorectomy, and chemoprevention in preventing breast cancer and improving survival of BRCA1 and BRCA2 carriers. This collective review highlights radiologic screening of patients with this genetic predisposition for cancer as well as discusses cancer risk reduction strategies and reproductive concerns in female BRCA1/2 mutation carriers. It has now been well documented that magnetic resonance imaging (MRI) of the breast has a higher sensitivity than mammography for the diagnosis of breast cancer in patients predisposed to breast cancer. We also emphasize that a new diagnostic device, molecular breast imaging (MBI), is now available and may be as sensitive as MRI. To date, this exciting technology, MBI, has not been used in studies of patients with BRCA1/2 genes. We also discuss in more detail the unique psychological ramifications of female BRCA1/2 mutation carriers. These women face unique choices regarding management of their high risk for breast and ovarian cancer that impact their reproductive options. Despite their high levels of concern, few female BRCA1/2 mutation carriers consider assisted reproduction technologies such as pregnancy surrogate, cryopreservation of oocytes or embryos, or implantation genetic diagnosis to select embryos without BCRA1/2 mutation. Further research must be undertaken to explore the risk management of patients with inherited cancer predisposition and to incorporate these preferences into clinical care.

CITADO POR
  1. Sariri Elaheh, Kashanian Maryam, Vahdat Mansoureh, Yari Saeedeh, Comparison of the dermatoglyphic characteristics of women with and without breast cancer, European Journal of Obstetrics & Gynecology and Reproductive Biology, 160, 2, 2012. Crossref

  2. Tabariès Sébastien, Siegel Peter M., Breast Cancer Liver Metastasis, in Liver Metastasis: Biology and Clinical Management, 16, 2011. Crossref

  3. Ly Adama, 7. Progression des cancers en Afrique : caractéristiques, altérité, nouvelles approches de santé publique, in Santé internationale , 2011. Crossref

  4. Misra Smita, Sharma Shvetank, Agarwal Anupriya, Khedkar Sheetal V, Tripathi Manish K, Mittal Mukul K, Chaudhuri Gautam, Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells, Molecular Cancer, 9, 1, 2010. Crossref

  5. Annoni Anna Maria, Longhini Claudia, Toland Amanda Ewart, Investigating men’s motivations to engage in genetic screening for BRCA1 and BRCA2 mutations, PLOS ONE, 17, 3, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain